| Abstract: | Epidemiological observations suggest that insulin‐like growth factor‐I (IGF‐I), a potent mitogenic and anti‐apoptotic peptide, plays a role in the etiology of breast cancer. Estrogen, which is crucial in breast carcinogenesis, both regulates and is influenced by IGF‐I family. A case‐control study was conducted to assess the role of IGF‐I as a biomarker for breast cancer and to evaluate the potential joint effect of circulating IGF‐I and critical period of estrogen exposure, as estimated by the interval between age at menarche and age at first full‐term pregnancy on the risk of breast cancer. Questionnaire information and blood samples were taken before treatment from 297 incident cases with breast cancer and 593 controls admitted for health examination at the Tri‐Service General Hospital, Taipei between 2004 and 2006. Plasma levels of IGF‐I and IGFBP‐3 were measured by immunoradiometric assay. Conditional logistic regression was used to calculate odds ratios (ORs) and their 95% confidence intervals (CIs). Our case‐control data indicate that breast cancer risk related to IGF‐I differs according to menopausal status. High circulating levels of IGF‐I increased risk of pre‐ but not postmenopausal breast cancer (top vs. bottom tertile, adjusted OR, 1.86; 95% CI, 1.01–3.44). Furthermore, elevated IGF‐I concentrations in conjunction with prolonged interval of critical period of estrogen exposure were associated with significantly increased risk of breast cancer, particularly among estrogen‐positive cases (adjusted OR, 2.42, 95% CI, 1.33–4.38). These results suggest that the joint effect of IGF‐I and estrogens may provide novel methods of breast cancer risk reduction among women. |
